VRTX VERTEX PHARMACEUTICALS INC Management Changes 8-K Filing 2025 - Appointments On May 14, 2025, Vertex Pharmaceuticals held its annual shareholders meeting, where board members were elected, the accounting firm Ernst & Young LLP was ratified, the 2024 executive compensation program was approved, and a proposal on excessive golden parachutes was rejected. Notably, Sangeeta Bhatia received 224 million votes in favor, while the shareholder proposal on golden parachutes garnered 141 million votes against.Get access to all SEC 8-K filings of the VERTEX PHARMACEUTICALS INC